CRISPR Therapy for Hereditary Angioedema Reduces Attack Rate by 87% Versus Placebo After a Single Dose in Phase 3
A single gene-editing treatment reduced attack frequency
In a phase 3 clinical trial in people with hereditary angioedema, the monthly attack rate during weeks 5–28 after dosing was 87% lower in the group that received a single intravenous dose of the in vivo CRISPR gene-editing therapy lonvoguran ziclumeran (lonvo-z) than in the placebo group. The results demonstrate an effect of a single dose in reducing attacks, but do not establish repair of the genetic defect or a lifelong cure.
Hereditary angioedema is a rare genetic disease that causes recurrent swelling attacks, severely disrupts daily life, and can be life-threatening. Lonvo-z is an investigational gene-editing therapy being developed as a one-time treatment. It is listed in the clinical trial registry under the development name NTLA-2002 and is described as a CRISPR/Cas9 system delivered by lipid nanoparticles (LNPs). The supplied abstract and registry record do not allow confirmation of the editing target or detailed molecular mechanism.
Placebo comparison in 80 patients with C1 inhibitor deficiency
The multinational, multicenter HAELO trial is a randomized, double-blind, placebo-controlled phase 3 study in people aged 16 years or older with hereditary angioedema and C1 inhibitor deficiency. A total of 80 participants were randomized in a 2:1 ratio: 52 received a single intravenous infusion of lonvo-z 50 mg, and 28 received a single intravenous infusion of placebo.
Under the enrollment criteria, patients had to agree not to use long-term prophylactic treatment from the start of screening through the end of the primary observation period, if the investigator considered this medically acceptable. They also had to have access to, and be able to use, treatment for attacks. Hereditary angioedema with normal C1 inhibitor was excluded. The results should therefore be interpreted in light of this patient population and these treatment conditions.
The primary endpoint was the monthly rate of investigator-confirmed attacks during weeks 5–28 after dosing. The comparison was based on the frequency of attacks confirmed by investigators, rather than recovery of protein levels or subjective improvement.
Monthly attack rates of 0.26 versus 2.10
The least-squares mean monthly attack rate during weeks 5–28 was 0.26 attacks per month in the lonvo-z group and 2.10 attacks per month in the placebo group. The respective 95% confidence intervals were 0.15–0.45 and 1.55–2.86 attacks per month. The relative difference versus placebo was −87% and was statistically significant (95% confidence interval, −93% to −78%; P<0.001). This is a comparison of attack rates between the two groups; it does not mean that attacks disappeared in every patient.
Adverse events occurring during or after treatment from the day of dosing through week 28 were reported in 92% of the lonvo-z group and 86% of the placebo group. Events that were more common in the lonvo-z group and occurred in more than 10% of that group included infusion-related reactions, headache, fatigue, back pain, and upper respiratory tract infection. No serious adverse events or grade 3 or higher adverse events were reported in the lonvo-z group. These results alone, however, cannot establish long-term safety.
Durability of effect and treatment burden remain to be assessed
As of February 10, 2026, the median follow-up was 7.5 months, with a range of 4.9–12.8 months. The registry record specifies a planned total of 104 weeks of observation after the first dose. After the 28-week primary observation period, participants have the option of receiving a single dose of the other treatment while remaining blinded, so the entire period cannot be considered placebo-controlled observation under the same treatment conditions.
The study was also designed to assess outcomes such as whether participants remain off long-term prophylactic treatment and whether they also avoid using treatment for attacks, but the supplied abstract does not report results for these long-term endpoints. The investigators concluded that a single dose of lonvo-z significantly reduced the attack rate compared with placebo. These data alone do not allow conclusions about a direct comparison with existing prophylactic treatments or the possibility of long-term treatment discontinuation. The study was supported by Intellia Therapeutics.
The key evidence is the PubMed abstract of the NEJM article and the HAELO clinical trial registry record.
New England Journal of Medicine, Ahead of Print.
This study provides evidence from a randomized, placebo-controlled phase 3 trial that a single in vivo gene-editing treatment can reduce attack frequency in patients. Its clinical relevance lies in assessing investigator-confirmed attacks, beyond molecular markers. However, the results were obtained under conditions in which patients did not use long-term prophylactic treatment and had access to treatment for attacks; they do not establish superiority to existing prophylactic treatments or that all treatment can be stopped. Further follow-up must establish how long attack suppression lasts, whether the burden of using prophylactic and on-demand treatment actually decreases, and whether long-term safety is maintained. Those findings will provide a basis for judging the lasting clinical value of a single dose.